TAK logo

TAKEDA PHARMACEUTIC-SP ADR

TAKNYSE
πŸ† #207 by market capEarnings Jan 27US Equity
$21.80β€”
Last available close Β· quote unavailable
πŸ””
Track TAK
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–² 1.7%
14dβ–² 3.7%
30dβ–² 7.7%
ytdβ–² 39.9%
1yβ–² 52.2%
🏦Market Cap
$69.45B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-1.7%
Declining
πŸ“ŠGross Margin
62.5%
High
πŸ’΅FCF Margin
12.5%
Healthy
βš–οΈP/S Ratio
2.4x
Cheap
Otter Score
72
Strong

Trading Snapshot

Day Range
β€”
52-Week Range
$14.16 – $22.07
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
3.19B
Next Earnings
2027-01-27

Fundamentals Snapshot

Annual Revenue
$4.78T
Last Q Revenue
$1.19T
P/E Ratio
28.5
P/S Ratio
2.4x
EPS (TTM)
$123.18
Dividend Yield
2.90%
Dilution (1yr)
+0.1%
TAK logo

TAKEDA PHARMACEUTIC-SP ADR

TAK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.5Tβ–Ό βˆ’1.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
65.1%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$6.2Bβ–Ό βˆ’98.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$626.8Bβ–Ό βˆ’7.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.21Bβ–² +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$4.2Tβ–² +$44.1B YoY
StockOtter Β· stockotter.space

About TAKEDA PHARMACEUTIC-SP ADR

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.